These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18695644

  • 1. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
    McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR.
    Br J Pharmacol; 2008 Nov; 155(5):690-701. PubMed ID: 18695644
    [Abstract] [Full Text] [Related]

  • 2. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
    Pathak V, Gault VA, Flatt PR, Irwin N.
    Mol Cell Endocrinol; 2015 Feb 05; 401():120-9. PubMed ID: 25449420
    [Abstract] [Full Text] [Related]

  • 3. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
    McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR.
    Am J Physiol Endocrinol Metab; 2007 Dec 05; 293(6):E1746-55. PubMed ID: 17848629
    [Abstract] [Full Text] [Related]

  • 4. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N, Hunter K, Montgomery IA, Flatt PR.
    Diabetes Obes Metab; 2013 Jul 05; 15(7):650-9. PubMed ID: 23388064
    [Abstract] [Full Text] [Related]

  • 5. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
    Gault VA, Kerr BD, Irwin N, Flatt PR.
    Biochem Pharmacol; 2008 Jun 15; 75(12):2325-33. PubMed ID: 18455149
    [Abstract] [Full Text] [Related]

  • 6. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
    Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.
    Diabetologia; 2007 Aug 15; 50(8):1752-62. PubMed ID: 17558485
    [Abstract] [Full Text] [Related]

  • 7. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
    Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.
    Diabetologia; 2007 Jul 15; 50(7):1532-40. PubMed ID: 17486314
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
    Irwin N, Montgomery IA, O'Harte FP, Frizelle P, Flatt PR.
    Int J Obes (Lond); 2013 Aug 15; 37(8):1058-63. PubMed ID: 23164696
    [Abstract] [Full Text] [Related]

  • 9. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
    Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR.
    Diabetes; 2005 Aug 15; 54(8):2436-46. PubMed ID: 16046312
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM, Irwin N, O'Flynn D, Franklin ZJ, Hewage CM, O'Harte FP.
    J Endocrinol; 2016 Jun 15; 229(3):319-30. PubMed ID: 27098830
    [Abstract] [Full Text] [Related]

  • 12. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.
    McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR.
    Diabetes Obes Metab; 2008 Apr 15; 10(4):336-42. PubMed ID: 18333892
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
    Irwin N, McClean PL, Hunter K, Flatt PR.
    Diabetes Obes Metab; 2009 Jun 15; 11(6):603-10. PubMed ID: 19515180
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.
    Tatarkiewicz K, Hargrove DM, Jodka CM, Gedulin BR, Smith PA, Hoyt JA, Lwin A, Collins L, Mamedova L, Levy OE, D'Souza L, Janssen S, Srivastava V, Ghosh SS, Parkes DG.
    Diabetes Obes Metab; 2014 Jan 15; 16(1):75-85. PubMed ID: 23859463
    [Abstract] [Full Text] [Related]

  • 17. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.
    Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR.
    Biol Chem; 2009 Jan 15; 390(1):75-80. PubMed ID: 18937625
    [Abstract] [Full Text] [Related]

  • 18. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
    Irwin N, Hunter K, Flatt PR.
    Peptides; 2008 Jun 15; 29(6):1036-41. PubMed ID: 18291559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.